Currently, a few preclinical and clinical studies investigated targeting IL-6/STAT3 in therapy in GC, and the findings of our study provide a solid theoretical support for clinical applications of anti-IL-6 strategy of treatment of GC metastasis. This evidence concerns the gene IL6 and gastric cancer.